Poinciana Advisors Group LLC Invests $279,000 in Natera, Inc. (NASDAQ:NTRA)

Poinciana Advisors Group LLC purchased a new position in shares of Natera, Inc. (NASDAQ:NTRAFree Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,763 shares of the medical research company’s stock, valued at approximately $279,000.

A number of other large investors have also modified their holdings of the business. Wellington Management Group LLP grew its stake in shares of Natera by 205.4% during the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock worth $355,493,000 after acquiring an additional 1,883,481 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Natera by 3.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company’s stock worth $315,194,000 after acquiring an additional 85,236 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Natera by 7.4% during the third quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company’s stock worth $265,747,000 after acquiring an additional 143,825 shares during the last quarter. Maverick Capital Ltd. boosted its position in Natera by 25.2% in the third quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company’s stock valued at $170,119,000 after buying an additional 269,706 shares during the last quarter. Finally, Castle Hook Partners LP boosted its position in Natera by 27.4% in the third quarter. Castle Hook Partners LP now owns 1,140,090 shares of the medical research company’s stock valued at $144,734,000 after buying an additional 245,505 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Stock Performance

NASDAQ NTRA opened at $148.22 on Friday. The stock has a market cap of $20.04 billion, a PE ratio of -84.22 and a beta of 1.80. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a twelve month low of $83.13 and a twelve month high of $183.00. The stock has a fifty day simple moving average of $164.09 and a 200-day simple moving average of $148.21.

Natera (NASDAQ:NTRAGet Free Report) last released its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. The business had revenue of $476.10 million during the quarter, compared to analysts’ expectations of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Equities analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on NTRA. Piper Sandler upped their target price on Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Tuesday, March 4th. Royal Bank of Canada began coverage on Natera in a research report on Thursday. They issued an “outperform” rating and a $251.00 target price on the stock. Canaccord Genuity Group reiterated a “buy” rating and issued a $180.00 target price on shares of Natera in a research report on Wednesday, February 26th. Guggenheim upped their target price on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 17th. Finally, JPMorgan Chase & Co. upped their target price on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $178.12.

Check Out Our Latest Stock Analysis on NTRA

Insider Activity at Natera

In related news, insider Solomon Moshkevich sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $143.29, for a total transaction of $859,740.00. Following the completion of the transaction, the insider now directly owns 143,768 shares in the company, valued at $20,600,516.72. This trade represents a 4.01 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider John Fesko sold 663 shares of the firm’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $177.77, for a total value of $117,861.51. Following the transaction, the insider now owns 156,044 shares of the company’s stock, valued at $27,739,941.88. This trade represents a 0.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 298,946 shares of company stock worth $47,803,462 in the last three months. 7.60% of the stock is owned by company insiders.

Natera Profile

(Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Featured Stories

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRAFree Report).

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.